Haemonetics Expands Viscoelastic Testing Capabilities with FDA Cleared TEG 6s Hemostasis Cartridge
Thursday, 4 April 2024, 21:01
Haemonetics Receives FDA Clearance for TEG 6s Hemostasis Cartridge
Haemonetics has received FDA clearance for the TEG 6s global Hemostasis-HN assay cartridge, enhancing viscoelastic testing capabilities for heparinized patients. This approval marks a significant milestone in improving testing precision and efficiency in hemostasis management.
Benefits of the TEG 6s Hemostasis Cartridge:
- Enhanced Testing Capabilities: The cartridge expands options for viscoelastic testing, allowing for more precise assessment of hemostatic parameters.
- Improved Patient Care: Healthcare professionals can now better manage heparinized patients with the enhanced testing capabilities offered by the cartridge.
The expansion in testing options offered by Haemonetics is set to benefit healthcare professionals and patients alike, ensuring better outcomes in managing hemostatic abnormalities.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.